Get the Stockscreener App
100.04
3.04%
2.95
After Hours:
97.55
-2.49
-2.49%
Glaukos Corporation stock is traded at $100.04, with a volume of 809.63K.
It is up +3.04% in the last 24 hours and down -16.65% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$97.09
Open:
$95.08
24h Volume:
809.63K
Relative Volume:
1.02
Market Cap:
$5.49B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-33.80
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-3.00%
1M Performance:
-16.65%
6M Performance:
-22.13%
1Y Performance:
+11.80%
1-Day Range:
$94.15
$100.56
1-Week Range:
$94.15
$105.07
52-Week Range:
$89.94
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
100.04 | 5.49B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
131.93 | 228.81B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - TradingView
Learn to Evaluate (GKOS) using the Charts - news.stocktradersdaily.com
Glaukos CFO Thurman Alex R. sells $162k in stock By Investing.com - Investing.com South Africa
Glaukos CFO Thurman Alex R. sells $162k in stock - Investing.com
Glaukos Corporation (NYSE:GKOS) Is Expected To Breakeven In The Near Future - simplywall.st
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS) - Yahoo Finance
Primecap Management Co. CA Has $182.08 Million Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
First Week of May 16th Options Trading For Glaukos (GKOS) - Nasdaq
(GKOS) Trading Report - Stock Traders Daily
Glaukos, RadiusXR, and Topcon Healthcare Work to Advance Vision Testing - Medical Product Outsourcing
RadiusXR and Glaukos Announce a New Collaboration With Topcon Healthcare, Inc., and the Launch of Inspire - Vision Monday
Here's Why You Should Retain Glaukos Stock in Your Portfolio - MSN
Glaukos Licenses Iveena’s Investigational Keratoconus Therapy - Business Wire
Midday Stock Roundup: Xponential Fitness Plunges 38%, GEN Restaurant Group Up 10% - Orange County Business Journal
Glaukos Highlights Strategic Focus in 2024 Presentation - TipRanks
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution - 01Net
Glaukos, RadiusXR collaborate with Topcon Healthcare on vision testing platform - TipRanks
Glaukos Unveils Game-Changing Vision Diagnostic Wearable: First-Ever Platform for Glaucoma Testing - Stock Titan
Where are the Opportunities in (GKOS) - news.stocktradersdaily.com
US Bancorp DE Acquires 470 Shares of Glaukos Co. (NYSE:GKOS) - Defense World
Glaukos Co. (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Glaukos Corp. to Host Earnings Call - ACCESS Newswire
289 Shares in Glaukos Co. (NYSE:GKOS) Bought by IFP Advisors Inc - Defense World
Bank of New York Mellon Corp Increases Holdings in Glaukos Co. (NYSE:GKOS) - Defense World
Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts? - Insider Monkey
Glaukos, Tarsus, RxSight: Q4 Earnings Snapshot - Orange County Business Journal
Stifel maintains Buy on Glaukos stock, reiterates $175 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Glaukos stock, reiterates $175 target - Investing.com
Truist Financial Corp Sells 5,319 Shares of Glaukos Co. (NYSE:GKOS) - Defense World
7 Best Medical Technology Stocks To Buy According To Analysts - Insider Monkey
Glaukos CEO Makes a Multi-Million Dollar Stock Sale! - TipRanks
Glaukos director Mark Foley sells common stock for $2.5 million By Investing.com - Investing.com Australia
Glaukos director Mark Foley sells common stock for $2.5 million - Investing.com
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock? - MSN
Glaukos Corporation (NYSE:GKOS) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless - Simply Wall St
(GKOS) Investment Report - Stock Traders Daily
Glaukos Co. (NYSE:GKOS) Shares Sold by Taylor Frigon Capital Management LLC - MarketBeat
FDA accepts Glaukos application for Epioxa for keratoconus - MSN
CIBC Asset Management Inc Makes New Investment in Glaukos Co. (NYSE:GKOS) - Defense World
Needham & Company LLC Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock - MarketBeat
GLAUKOS Corp SEC 10-K Report - TradingView
FDA sets review date for Glaukos’ keratoconus drug By Investing.com - Investing.com Australia
GKOSGlaukos Corp Latest Stock News & Market Updates - StockTitan
FDA gives Glaukos ‘Day 74’ notice for Epioxa NDA to treat keratoconus - TipRanks
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today - Benzinga
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery - Benzinga India
Glaukos Announces FDA Acceptance Of NDA Submission For Epioxa(TM) -February 24, 2025 at 08:24 am EST - Marketscreener.com
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ - BioSpace
FDA sets review date for Glaukos' keratoconus drug - Investing.com India
Glaukos's Corneal Disease Drug Accepted for FDA Review -February 24, 2025 at 07:33 am EST - Marketscreener.com
FDA sets review date for Glaukos' keratoconus drug By Investing.com - Investing.com South Africa
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):